Patents by Inventor Daniel Tavares

Daniel Tavares has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11198736
    Abstract: The invention generally relates to antibodies that bind to human folate receptor and diagnostic assays for folate receptor 1-based therapies. Methods of using the antibodies to monitor therapy are further provided.
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: December 14, 2021
    Assignee: ImmunoGen, Inc.
    Inventors: Olga Ab, Daniel Tavares, Juliantro Setiady, Sharron Ladd, Christina N. Carrigan, Lingyun Rui
  • Publication number: 20210347888
    Abstract: Antibodies, fragments thereof and fusion proteins that specifically bind to CD19, are described, as well as methods of making and using such antibodies. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various B-cell disorders, including B-cell malignancies and autoimmune diseases.
    Type: Application
    Filed: April 23, 2021
    Publication date: November 11, 2021
    Inventors: Daniel Tavares, Bianka Prinz, James Geoghegan
  • Patent number: 11104740
    Abstract: The invention generally relates to antibodies that bind to human CD37 and diagnostic assays for CD37-based therapies.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: August 31, 2021
    Assignee: DEBIOPHARM INTERNATIONAL, S.A.
    Inventors: Jutta Deckert, Daniel Tavares, Lingyun Rui, Sven Loebrich, Meghan Puopolo
  • Patent number: 10988531
    Abstract: The invention relates to novel cell-binding agent-cytotoxic agent conjugates, wherein the cell-binding agent (CBA) is covalently linked to the cytotoxic agent through an aldehyde group obtained from oxidation of a 2-hydroxyethylamine moiety on the CBA. The invention also provides methods of preparing the conjugates of the present invention. The invention further provides composition and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the conjugates of the invention.
    Type: Grant
    Filed: September 2, 2015
    Date of Patent: April 27, 2021
    Assignee: IMMUNOGEN, INC.
    Inventors: Nathan Elliott Fishkin, Daniel Tavares, Lingyun Rui, Luke B. Harris, Manami Shizuka, Michael Louis Miller, Ravi V. J. Chari
  • Publication number: 20210032327
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Application
    Filed: July 21, 2020
    Publication date: February 4, 2021
    Applicant: ImmunoGen, Inc.
    Inventors: Olga AB, Daniel Tavares, Lingyun Rui, Gillian Payne, Viktor S. Goldmakher
  • Publication number: 20200408765
    Abstract: Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to CD38, are capable of killing CD38+ cells by apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and/or complement-dependent cytotoxicity (CDC). Said antibodies and fragments thereof may be used in the treatment of tumors that express CD38 protein, such as multiple myeloma, chronic lymphocytic leukemia, chronic myelogenous leukemia, acute myelogenous leukemia, or acute lymphocytic leukemia, or the treatment of autoimmune and inflammatory diseases such as systemic lupus, rheumatoid arthritis, multiple sclerosis, erythematosus, and asthma. Said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of CD38.
    Type: Application
    Filed: February 7, 2020
    Publication date: December 31, 2020
    Inventors: Peter U. PARK, Laura M. BARTLE, Anna SKALETSKAYA, Viktor GOLDMAKHER, Daniel TAVARES, Jutta DECKERT, Vincent MIKOL, Veronique BLANC
  • Publication number: 20200333347
    Abstract: The invention generally relates to antibodies that bind to human folate receptor 1 and diagnostic assays for folate receptor 1-based therapies. Methods of using the antibodies to monitor therapy are further provided.
    Type: Application
    Filed: February 28, 2020
    Publication date: October 22, 2020
    Inventors: Christina N. CARRIGAN, Olga AB, Daniel TAVARES, Beni B. WOLF, Nathan E. TESTA
  • Publication number: 20200325240
    Abstract: The invention generally relates to antibodies that bind to human folate receptor and diagnostic assays for folate receptor 1-based therapies. Methods of using the antibodies to monitor therapy are further provided.
    Type: Application
    Filed: December 9, 2019
    Publication date: October 15, 2020
    Inventors: Olga AB, Daniel TAVARES, Julianto SETIADY, Sharron LADD, Christina N. CARRIGAN, Lingyun RUI
  • Patent number: 10752683
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: August 25, 2020
    Assignee: ImmunoGen, Inc.
    Inventors: Olga Ab, Daniel Tavares, Lingyun Rui, Gillian Payne, Viktor S. Goldmakher
  • Patent number: 10718448
    Abstract: A reelable pipeline includes a pipe-in-pipe section and a single pipe section coupled to the pipe-in-pipe section. The single pipe section has a bending stiffness that is different from the bending stiffness of the pipe-in-pipe section. The reelable pipeline includes a transition piece connected between the pipe-in-pipe section and the single pipe section and having a bending stiffness that varies along its length.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: July 21, 2020
    Assignee: EQUINOR ENERGY AS
    Inventors: Geir Endal, Stein R Giske, Andreia Cordeiro, Luis Daniel Tavares Nogueira
  • Patent number: 10613093
    Abstract: The invention generally relates to antibodies that bind to human folate receptor 1 and diagnostic assays for folate receptor 1-based therapies. Methods of using the antibodies to monitor therapy are further provided.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: April 7, 2020
    Assignee: ImmunoGen, Inc.
    Inventors: Christina N. Carrigan, Olga Ab, Daniel Tavares, Beni B. Wolf
  • Patent number: 10544230
    Abstract: The invention generally relates to antibodies that bind to human folate receptor and diagnostic assays for folate receptor 1-based therapies. Methods of using the antibodies to monitor therapy are further provided.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: January 28, 2020
    Assignee: ImmunoGen, Inc.
    Inventors: Olga Ab, Daniel Tavares, Julianto Setiady, Sharron Ladd, Christina N. Carrigan, Lingyun Rui
  • Publication number: 20190345248
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Application
    Filed: April 15, 2019
    Publication date: November 14, 2019
    Applicant: ImmunoGen, Inc.
    Inventors: Olga AB, Daniel TAVARES, Lingyun RUI, Gillian PAYNE, Viktor S. GOLDMAKHER
  • Publication number: 20190271412
    Abstract: A reelable pipeline includes a pipe-in-pipe section and a single pipe section coupled to the pipe-in-pipe section. The single pipe section has a bending stiffness that is different from the bending stiffness of the pipe-in-pipe section. The reelable pipeline includes a transition piece connected between the pipe-in-pipe section and the single pipe section and having a bending stiffness that varies along its length.
    Type: Application
    Filed: October 12, 2017
    Publication date: September 5, 2019
    Applicant: Equinor Energy AS
    Inventors: Geir ENDAL, Stein R GISKE, Andreia CORDEIRO, Luis Daniel Tavares NOGUEIRA
  • Publication number: 20190227073
    Abstract: The invention generally relates to antibodies that bind to human folate receptor 1 and diagnostic assays for folate receptor 1-based therapies. Methods of using the antibodies to monitor therapy are further provided.
    Type: Application
    Filed: November 28, 2018
    Publication date: July 25, 2019
    Inventors: Christina N. Carrigan, Olga Ab, Daniel Tavares, Beni B. Wolf
  • Publication number: 20190218303
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to CD37 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Application
    Filed: December 17, 2018
    Publication date: July 18, 2019
    Inventors: Jutta Deckert, Peter Park, Daniel Tavares, Lingyun Rui
  • Patent number: 10301385
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Grant
    Filed: May 1, 2017
    Date of Patent: May 28, 2019
    Assignee: ImmunoGen, Inc.
    Inventors: Olga Ab, Daniel Tavares, Lingyun Rui, Gillian Payne, Viktor S. Goldmakher
  • Patent number: 10202460
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to CD37 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: February 12, 2019
    Assignee: Debiopharm International, S.A.
    Inventors: Jutta Deckert, Peter Park, Daniel Tavares, Lingyun Rui
  • Publication number: 20190023805
    Abstract: The invention generally relates to antibodies that bind to human folate receptor and diagnostic assays for folate receptor 1-based therapies. Methods of using the antibodies to monitor therapy are further provided.
    Type: Application
    Filed: June 7, 2018
    Publication date: January 24, 2019
    Inventors: Olga AB, Daniel TAVARES, Julianto SETIADY, Sharron LADD, Christina N. CARRIGAN, Lingyun RUI
  • Patent number: 10180432
    Abstract: The invention generally relates to antibodies that bind to human folate receptor 1 and diagnostic assays for folate receptor 1-based therapies. Methods of using the antibodies to monitor therapy are further provided.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: January 15, 2019
    Assignee: ImmunoGen, inc.
    Inventors: Christina N. Carrigan, Olga Ab, Daniel Tavares, Beni B. Wolf